Free Alerts   Login
Health Care › Biological Products (No Diagnostic Substances)

DNLI Stock Price Correlated With Denali Therapeutics Financials

DNLI Stock Price vs. Quarterly
DNLI
Income Statement
Cash Flow
Balance Sheet

DNLI Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

DNLI Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

DNLI Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Baillie Gifford
14,260,724 sh
-420,303 sh
-3%
$306,035
$3,166
Blackrock.
11,543,446 sh
658,150 sh
6%
$247,724
$23,161
Vanguard Group
10,834,483 sh
236,702 sh
2%
$232,508
$13,875
Wellington Management Group Llp
7,274,717 sh
-14,243 sh
0%
$156,116
$5,745
Temasek Holdings (Private)
6,895,992 sh
 
$147,988
Crestline Management, Lp
5,660,732 sh
-300,000 sh
-5%
$121,479
-$1,491
State Street
5,485,948 sh
1,210,620 sh
28%
$117,728
$29,528
Capital Research Global Investors
2,909,528 sh
29,205 sh
1%
$62,438
$3,017
Geode Capital Management
2,659,296 sh
127,461 sh
5%
$57,075
$4,837
Baker Bros. Advisors Lp
2,607,196 sh
315,193 sh
14%
$55,950
$8,666
Price T Rowe Associates /Md/
2,574,321 sh
-317,629 sh
-11%
$55
-$5
Flagship Pioneering.
2,319,968 sh
-300,000 sh
-11%
$49,787
-$4,263
Bank Of New York Mellon
1,870,627 sh
-93,061 sh
-5%
$40,143
-$369
Marshall Wace,
1,667,397 sh
1,667,397 sh
NEW
$35,782
$35,782
Credit Suisse Ag
1,576,221 sh
8,912 sh
1%
$33,826
$1,493
Federated Hermes.
1,351,900 sh
 
$29,012
Casdin Capital
1,300,000 sh
 
$27,898
Gilder Gagnon Howe & Co
1,219,392 sh
-26,807 sh
-2%
$26,168
$459
Norges Bank
1,152,646 sh
1,152,646 sh
NEW
$24,736
$24,736
Yiheng Capital
1,150,684 sh
 
$24,694

Free historical financial statements for Denali Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 24 quarters since 2018. Compare with DNLI stock chart to see long term trends.

Data imported from Denali Therapeutics Inc SEC filings. Check original filings before making any investment decision.